Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
14/03/2025 20:14
Avenue Therapeutics Inc ATXI.OQ ATXI.O is expected to show no change in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00, above its last closing price of $0.77. This summary was machine generated March 14 at 20:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary